Noninvasive diagnosis of chemotherapy induced liver injury by LiMAx test - Two case reports and a review of the literature

被引：8
作者：
Bednarsch J. [1 ]
Jara M. [1 ]
Lock J.F. [1 ]
Malinowski M. [1 ]
Pratschke J. [1 ]
Stockmann M. [1 ]
机构：
[1] Department of General, Visceral and Transplantation Surgery, Charité University Hospital, Augustenburger Platz 1, Berlin
来源：
BMC Research Notes | / 8卷 / 1期
关键词：
Chemotherapy induced liver injury; ICG-PDR; LiMAx; Liver function; Methacetin;
D O I：
10.1186/s13104-015-1055-6
中图分类号：
学科分类号：
摘要：
Background: Chemotherapy-induced liver injury is a well-known phenomenon after neoadjuvant therapy of liver metastasis and contributes to postoperative morbidity and mortality. Still there is no suitable test available to reliably determine functional impairment and hepatic regeneration after chemotherapy. Case presentation: We report two cases of caucasian patients who underwent repeated liver function assessments using LiMAx (maximum liver function capacity), Indocyanine plasma disappearance rate and biochemical liver function parameters in the course of adjuvant oxaliplatin-based chemotherapy. Both patients yielded a decrease from their initial liver function determined by LiMAx. Liver regeneration assessed functional recovery within 4 weeks in case of mild functional impairment after cessation of chemotherapy or within 8 weeks in case of major functional deterioration. Indocyanine plasma disappearance rate and biochemical parameters remained stable or without a clear trend in case of minor functional impairment. This is the first report using a dynamic liver function test to evaluate the impact and recovery from chemotherapy associated liver injury. Conclusions: The LiMAx test might be a sensitive tool to diagnose mild functional impairment after chemotherapy when standard liver function tests have remained within normal ranges and might be capable to assess the course of regeneration after chemotherapy. This could be useful to optimize individual chemotherapy-free interval before liver surgery can be carried out safely. © 2015 Bednarsch et al.; licensee BioMed Central.
引用
收藏
相关论文
共 30 条
[1]  
Vauthey J.N., Pawlik T.M., Ribero D., Wu T.T., Zorzi D., Hoff P.M., Et al., Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases, J Clin Oncol, 24, pp. 2065-2072, (2006)
[2]  
Karoui M., Penna C., Amin-Hashem M., Mitry E., Benoist S., Franc B., Et al., Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases, Ann Surg, 243, pp. 1-7, (2006)
[3]  
Nordlinger B., Sorbye H., Glimelius B., Poston G.J., Schlag P.M., Rougier P., Et al., Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial, Lancet, 371, pp. 1007-1016, (2008)
[4]  
Folprecht G., Gruenberger T., Bechstein W.O., Raab H.R., Lordick F., Hartmann J.T., Et al., Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomised phase 2 trial, Lancet Oncol, 11, pp. 38-47, (2010)
[5]  
Garufi C., Torsello A., Tumolo S., Ettorre G.M., Zeuli M., Campanella C., Et al., Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial, Br J Cancer, 103, pp. 1542-1547, (2010)
[6]  
Saltz L.B., Clarke S., Diaz-Rubio E., Scheithauer W., Figer A., Wong R., Et al., Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study, J Clin Oncol, 26, pp. 2013-2019, (2008)
[7]  
Nakano H., Oussoultzoglou E., Rosso E., Casnedi S., Chenard-Neu M.P., Dufour P., Et al., Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy, Ann Surg, 247, pp. 118-124, (2008)
[8]  
Aloia T., Sebagh M., Plasse M., Karam V., Levi F., Giacchetti S., Et al., Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases, J Clin Oncol, 24, pp. 4983-4990, (2006)
[9]  
Rubbia-Brandt L., Audard V., Sartoretti P., Roth A.D., Brezault C., Le Charpentier M., Et al., Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer, Ann Oncol, 15, pp. 460-466, (2004)
[10]  
Rubbia-Brandt L., Lauwers G.Y., Wang H., Majno P.E., Tanabe K., Zhu A.X., Et al., Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis, Histopathology, 56, pp. 430-439, (2010)
123